Efruxifermin Cirrhotic MASH Data — EASL Congress
Late-breaking efruxifermin data in compensated cirrhotic (F4) MASH patients at EASL. REZDIFFRA is not approved in cirrhotics. Watch: % achieving ≥1-stage fibrosis improvement, no-MASH-worsening rate.
What’s at stake
Efruxifermin is a weekly subcutaneous Fc-fusion analog of fibroblast growth factor 21 (FGF21) — a liver-secreted hormone regulating fat metabolism, insulin sensitivity, and energy balance — developed by Akero Therapeutics for MASH. The Fc-fusion domain extends the half-life of FGF21 from minutes to a week, enabling once-weekly dosing. Akero is evaluating efruxifermin in Phase 3 trials in both pre-cirrhotic (F2/F3) and cirrhotic (F4) MASH; REZDIFFRA, the only approved MASH drug, was not studied in cirrhotic patients, leaving that population entirely without an approved option.
No primer in glossary yet.
Major hepatology meeting. June; the lead venue for MASH/NASH and hepatitis readouts.
- MASHdiseaseMetabolic-Associated Steatohepatitis
Liver inflammation caused by fat accumulation, with metabolic risk factors. Renamed from NASH in 2023. Resmetirom (REZDIFFRA) is the only approved therapy.
- EASLconferenceEuropean Association for the Study of the Liver Congress
Major hepatology meeting. June; the lead venue for MASH/NASH and hepatitis readouts.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| REZDIFFRAresmetirom | MDGL | small molecule | thyroid hormone receptor-β agonist | INTERIM · Oct 26 |
Disclosure trail
- Apr 9, 2026·21d agopinned · highest confidenceHIGH confPREXACTtop claimMAY 062026
“A late-breaking oral presentation of efruxifermin data in compensated cirrhotic MASH patients is scheduled for the EASL Congress on May 6, 2026.”
conf 92%via llm